On November 7, 2023 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported its business update and its financial position for the quarter ending September 30, 2023 (Press release, Transgene, NOV 7, 2023, View Source [SID1234637184]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the third quarter of 2023, Transgene’s clinical-stage immunotherapy portfolio continued to advance. Notable progress included the treatment of the first patient in the Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA (pembrolizumab) (NCT: 04725331).
In the next 12 months, key expected catalysts include:
– Updated data from the ongoing Phase I trial of the neoantigen cancer vaccine TG4050 in the adjuvant treatment of head and neck cancer in H1 2024 and the launch of a randomized Phase II trial in 2024,
– Data read out from ongoing randomized Phase II trial of TG4001 in HPV+ anogenital cancers in 2024,
– Completion of the Phase I trial of TG6050 administered intravenously in non-small cell lung cancer,
– The inclusion of the last patient in the Part B of the Phase I study of BT-001 in solid tumors in H1 2024.
Operating income
First Nine Months
Q3
In millions of euros
2023
2022
2023
2022
Revenue from collaborative and licensing agreements
1.2
3.0
–
0.7
Government financing for research expenditures
4.8
5.2
1.3
1.5
Other income
0.2
0.2
0.1
0.1
Operating revenue
6.2
8.4
1.4
2.3
During the first nine months of 2023, operating revenue amounted to €6.2 million compared to €8.4 million in the same period in 2022. They are mainly derived from the research tax credit (€4.8 million for the first nine months of 2023, compared to €5.2 million for the same period in 2022) and Transgene’s collaboration agreement with AstraZeneca on the Invir.IO program.
Revenue from collaborative and licensing agreements amounted to €1.2 million in the first nine months of 2023, compared with €3 million in the same period in 2022. In the first half of 2023, AstraZeneca informed Transgene of its decision to end the collaboration.
Cash, cash equivalents and other financial assets
Cash, cash equivalents and other financial assets stood at €16.4 million as of September 30, 2023, compared to €26.8 million as of December 31, 2022. In the first nine months of 2023, Transgene’s cash burn amounted to €13.8 million compared to a cash burn of €13.3 million for the same period in 2022.
During the reporting period, the Company reached an agreement for the sale of its remaining shares held in Tasly BioPharmaceuticals for a total amount of US$15.3 million (€14 million). The transaction was closed in July 2023 upon receipt of the funds.
On September 20, 2023, the Company signed a current account advance agreement with Institut Mérieux (TSGH) for a maximum of €36 million. The credit facility has a 24-month term and Transgene is able to draw on and repay the facility at its discretion. As of September 30, 2023, the Company had drawn €3.4 million on this facility.
This non-dilutive credit facility extends Transgene’s financial visibility until the end of 2024, enabling the Company to deliver significant milestones on key portfolio projects in the next 12 months.